STOCK TITAN
  1. Home
  2. News
  3. TTNP

TITAN PHARMACEUTICAL INC - $TTNP STOCK NEWS

Welcome to our dedicated page for TITAN PHARMACEUTICAL news (Ticker: $TTNP), a resource for investors and traders seeking the latest updates and insights on TITAN PHARMACEUTICAL stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TITAN PHARMACEUTICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TITAN PHARMACEUTICAL's position in the market.

News
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Rhea-AI Summary
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has regained compliance with the minimum $1.00 bid price requirement and satisfies all criteria for continued listing on The Nasdaq Capital Market. The listing matter has been closed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
News
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
Rhea-AI Summary
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has approved a 1-for-20 reverse stock split, effective on January 9, 2024. The reverse split will combine 20 shares into one and result in approximately 781,503 shares of common stock issued and outstanding. The stock options and warrants will be proportionally adjusted, and the common shares will continue to trade under the symbol 'TTNP.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.24%
Tags
none
-
News
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
Rhea-AI Summary
Titan Pharmaceuticals announces new appointments to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
management
News
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
Rhea-AI Summary
Titan Pharmaceuticals announces sale of Series AA Convertible Preferred Stock to Sire Group for $9.5 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
News
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
Rhea-AI Summary
Titan Pharmaceuticals announces the sale of certain ProNeura assets to Fedson, Inc. for $2 million upfront with the potential for up to $50 million in milestone payments and single digit royalty payments on future net sales. The transaction allows Titan to focus on extracting value from their principal asset, TP-2021 for the treatment of pruritus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.46%
Tags
none
-
News
Titan Pharmaceuticals Provides Shareholder Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
none
News
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
-
News
Titan Pharmaceuticals Announces Board Expansion and Management Changes
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
-
News
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.09%
Tags
none
News
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Stock TTNP logo
TITAN PHARMACEUTICAL INC

Nasdaq:TTNP

TTNP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TTNP Stock Data

6.13M
699.98k
45.47%
5.51%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About TTNP

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.